In conclusion, our data revealed that paeoniflorin promotes SIRT4 expression to enhance the sensitivity of ER-positive breast cancer cells to tamoxifen by suppressing STAT3 activation, suggesting that paeoniflorin could be used as a drug candidate for the treatment of ER + breast cancer. This evidence concerns the gene STAT3 and breast carcinoma.